Surgery + diabetes drug: a new One-Two punch against severe obesity?

NCT ID NCT07336862

Recruiting now Disease control Sponsor: China-Japan Friendship Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether adding a GLP-1 drug (semaglutide) to bariatric surgery helps people with severe obesity lose more weight and keep it off. About 200 adults aged 18-60 with a BMI of 35 or higher and related health issues will be followed for a year. The goal is to see if the combination works better than surgery alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide (a GLP-1 receptor agonist) plus laparoscopic sleeve gastrectomy
What this could lead to: If successful, this combination could offer a more effective long-term weight-loss strategy for people with severe obesity, reducing weight regain and improving metabolic conditions like diabetes.
What could go wrong: This is an early-phase study with only 200 participants, so results may not apply to everyone. The added drug carries risks like nausea or gastrointestinal issues, and long-term benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

morbid obesity Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Locations

China-Japan Friendship Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.